Therapeutics News and Research

RSS

Accurexa seeks FDA clearance to market BranchPoint device

Accurexa Inc., a biotechnology company focused on developing and commercializing novel neurological therapies, announced on Monday that it has filed a submission with the U.S. FDA for 510(k) clearance to market its BranchPoint device.

17 Jun 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

Women with significant depressive symptoms have lower levels of klotho hormone

Women under chronic stress have significantly lower levels of klotho, a hormone that regulates aging and enhances cognition, researchers at UC San Francisco have found in a study comparing mothers of children on the autism spectrum to low-stress controls.

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

Scientists identify two new key players involved in development of prostate cancer

Understanding how a normal healthy cell turns into a cancerous one is our best bet yet for beating the disease. It will help better diagnose the cancer type, and enable the development of more effective, and less toxic therapies. But cells have evolved all sorts of sophisticated ways to become cancerous, and identifying the molecules involved and how they function in each type of cancer is a major undertaking.

16 Jun 2015

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.

16 Jun 2015

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.

16 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.

16 Jun 2015

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.

16 Jun 2015

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Department of Emergency Medicine at Stony Brook University School of Medicine.

16 Jun 2015

Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Mayo Clinic in Jacksonville, Fla., and United Therapeutics Corporation today announced a collaboration to build and operate a lung restoration center on the Mayo campus. The goal is to significantly increase the volume of lungs for transplantation by preserving and restoring selected marginal donor lungs, making them viable for transplantation. The restored lungs will be made available to patients at Mayo Clinic and other transplant centers throughout the United States.

16 Jun 2015

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company's orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication.

15 Jun 2015

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.

15 Jun 2015

Experimental drug improves failing heart's function

An experimental drug improves the ability of heart muscle cells damaged by heart failure to pump blood, according to the results of a study led by Icahn School of Medicine at Mount Sinai researchers and published online today in Nature Communications.

14 Jun 2015

New TSRI study integrates neuroscience and psychological research to understand sleep, memory

In Macbeth, Shakespeare describes sleep as "the death of each day's life," but he may have gotten it wrong. Sleep, as it turns out, may be the one thing that keeps our memories alive and intact.

12 Jun 2015

USC Stem Cell scientist named 2015 Pew-Stewart scholar for cancer research

USC Stem Cell researcher Min Yu, MD, PhD, is one of five early-career scientists to be named a 2015 Pew-Stewart scholar for cancer research. As part of this honor, she will receive $240,000 over four years to advance the understanding of metastatic breast cancer.

11 Jun 2015

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

There is the Addams Family. And then there is the ADAMTS family. While one is mindless entertainment, the latter may prove to be a new genetic avenue for designing ovarian cancer treatment.

11 Jun 2015

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA).

11 Jun 2015

Study reveals new information about role of abdominal fat in teens with CAH

Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD).

11 Jun 2015

Therapeutics News and Research

Accurexa seeks FDA clearance to market BranchPoint device

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Women with significant depressive symptoms have lower levels of klotho hormone

CytomX closes $70 million Series D financing round

Scientists identify two new key players involved in development of prostate cancer

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Pulmatrix completes previously announced merger and closes $10 million in private placement

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Experimental drug improves failing heart's function

New TSRI study integrates neuroscience and psychological research to understand sleep, memory

USC Stem Cell scientist named 2015 Pew-Stewart scholar for cancer research

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Study reveals new information about role of abdominal fat in teens with CAH

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News